Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ultimate Nutrition law suit

This article was originally published in The Tan Sheet

Executive Summary

Ultimate Nutrition files a law suit in Connecticut Superior Court against Williamsport, Pa.-based Diamond Drinks, Suscon and Anthony Cenimo Jr.; and Stamford, Conn.-based MetaBEV and John Sbordone, seeking damages for a product the firm says is "unstable." The defendants helped manufacture a protein shake product for the firm and guaranteed the product would be "stable, with a one-year shelf life," according to Farmington, Conn.-based Ultimate Nutrition's release. The firm says it later found the product was not stable and requested that Diamond recall it, fix the problem and rerun the batch, but was forced to conduct the withdrawal itself because Diamond did not respond. The defendants' "negligence caused the product line to fail and hurt our reputation. We are seeking damages for the cost of manufacture, investment in advertising and marketing, and loss of good will and reputation in the industry," Ultimate Nutrition VP Brian Rubino says in a March 8 release...

You may also be interested in...



More Top-Level Pharma Changes In India, Cipla Gets CSO

Top-level personnel movement continues at pharma firms in India, with Cipla now appointing an ex-Amneal executive as its Chief Scientific Officer, while Abbott has effected a rejig at the helm.

India Acts To Limit Supply Disruption From Coronavirus

Indian pharmaceutical companies will soon be asked to seek a no objection certificate for the export of 12 APIs and their formulations, as the country deals with Chinese raw material supply disruptions on the back of the coronavirus crisis. However, the move is not expected to impact the export quantum for now.

Could Revisiting US Approval Decisions Become Less Rare?

While not identifying specific situations raising potential questions, the FDA commissioner uses his appearance at agency's annual rare disease event to advise regulatory decisions may be revisited as more data becomes available. 

Topics

UsernamePublicRestriction

Register

PS101515

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel